Eyelea Approved to Treat Wet AMD in Canada

November 8th, 2013 by FFB Canada

An additional treatment option for people with wet age-related macular degeneration (AMD) will soon be available in Canada. Health Canada has just approved Eyelea, a drug made and marketed by Bayer Inc. Eyelea (also known as aflibercept) is used to treat the most severe form of AMD known as wet AMD. The drug is given…

Read More

Drug for Dry AMD Looks Promising in Early Trials

September 16th, 2013 by FFB Canada

A new drug being developed by Roche Pharmaceuticals may slow vision loss due to dry age-related macular degeneration (dry AMD). Dry AMD causes the slow death of vision cells in the retina. It is the most common, early form of age-related macular degeneration. In people with dry AMD, the retina begins to thin and –…

Read More

New Partnership Aims to Identify Drugs Useful to Delay RP

September 12th, 2013 by FFB Canada

The Foundation Fighting Blindness is partnering with the the Canadian Institutes of Health Research (CIHR) to fund early studies of a potential drug treatment for retinitis pigmentosa. The studies, led by Dr. Uri Saragovi at the Jewish General Hospital in Montreal, are searching for drug compounds that would slow vision loss due to retinitis pigmentosa…

Read More

Canadian Scientists Show ‘Proof of Principle’ for LCA Gene Therapy

June 11th, 2013 by FFB Canada

Research led by Dr. Robert Molday at the University of British Columbia has shown that gene therapy designed to target the RD3 gene can protect light-sensing photoreceptors and restore visual function in mice. In humans, mutations in the RD3 gene interfere with the production of an essential protein in the eye and cause Leber congenital…

Read More

Valproic Acid: The Perils of Using Drugs Off-Label

May 27th, 2013 by FFB Canada

Almost three years ago, scientists at the University of Massachusetts Medical School reported on a preliminary clinical trial of the epilepsy drug, valproic acid, as potential treatment for autosomal dominant retinitis pigmentosa (adRP). The trial was a brief four month snap-shot of the treatment of 7 people, but its findings were exciting. In five out…

Read More

A Conversation with Yves Sauve about Vitamins & AMD

May 17th, 2013 by FFB Canada

A decade ago, AREDS (the Age-Related Eye Disease Study) showed that people with age-related macular degeneration (AMD) who regularly took a high-dose formula of antioxidant vitamins could reduce their risk of developing advanced AMD by about 25%.  Taking AREDS vitamins works, but could it work better? That is the question that the AREDS2 trial aimed…

Read More

Usher Syndrome Findings Focus on Genetic Knowledge & Ongoing Trial

May 9th, 2013 by FFB Canada

Two reports at ARVO may be of interest to people with Usher syndrome. The first focused on the largest ever study of the USH2A gene. The Genetics of USH2A We know that mutations in the USH2A gene are the commonest cause of both Usher syndrome and autosomal recessive retinitis pigmentosa (RP), but until now scientists…

Read More

Making Gene Therapy Useful for More Conditions

May 8th, 2013 by FFB Canada

Gene therapy is one promising approach to treating inherited retinal diseases. In this type of therapy uses a viral vector, a hollowed-out virus (with the disease-causing components removed). This viral vector is used to carry a healthy new gene into the cell.  In many types of inherited retinal disease, this healthy gene may be able…

Read More

Retinitis Pigmentosa Drug may have Long-Term Positive Effect

May 6th, 2013 by FFB Canada

Earlier this year, we reported on the Japanese glaucoma drug, unoprostone isopropyl, and its use for the treatment of retinitis pigmentosa.  In early trials of the drug to determine the best dosage (phase II trials), people taking the drug reported improvement in their night-time and dim-light vision. After six months of treatment of receiving the…

Read More

Vitamin Supplements & AMD

May 6th, 2013 by FFB Canada

Vitamin supplements are widely used by people with age-related macular degeneration (AMD) to slow the development of the disease. A large US study, called AREDS (age-related eye disease study), was completed several years ago, which showed that one formulation of vitamins, now called the AREDS formulation, could reduce the risk of developing advanced AMD by…

Read More